Verzenios ® (abemaciklib)

För fullständig produktresumé för Verzenios se FASS.

Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska

Hur skall Verzenios® ▼ (abemaciklib) doseras och administreras hos patienter med metastatisk bröstcancer?

Den rekommenderade dosen abemaciclib är 150 mg två gånger dagligen i kombination med endokrin behandling.

SE_cFAQ_ABE027_DOSING_ADMINISTRATION
SE_cFAQ_ABE027_DOSING_ADMINISTRATION
en-GB

How Long Should Patients take Abemaciclib? 

Patients should take abemaciclib without a treatment pause, as long as they benefit from the therapy or until unacceptable toxicity occurs.1

How Long Should Patients take Abemaciclib? 

Patients should take abemaciclib without a treatment pause, as long as they benefit from the therapy or until unacceptable toxicity occurs.1

How Is Abemaciclib Administered?

Patients should

  • take abemaciclib with or without food
  • avoid grapefruit or grapefruit juice
  • take the doses at the same times every day, and
  • swallow the tablet whole.1

When is Abemaciclib Dose Modification Necessary?

Dose modification is recommended based on individual safety and tolerability.

The management of adverse reactions, such as diarrhea, hematologic toxicities, hepatotoxicity, or pneumonitis, may require dose interruption, dose reduction, or both.2 

Please find detailed information in the Verzenios Summary of Product Characteristics.1 

How is an Abemaciclib Overdose Managed?

There is no known antidote for an abemaciclib overdose.2Patients may develop fatigue and diarrhoea. Provide general supportive care.1

Are Dose Modifications Necessary for Patients with Hepatic Impairment

Dose adjustments are only required for patients with severe hepatic impairment (Child-Pugh C). Decrease the dosing frequency to once daily in these patients. 

No dose adjustments are necessary for patients with mild (Child Pugh A) or moderate (Child Pugh B) hepatic impairment.1 

Are Dose Modifications Necessary for Patients with Renal Impairment?

No dose adjustment is required for patients with mild or moderate renal impairment. We have no data in patients with severe impairment or on dialysis.

References

1Verzenios [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

2Data on file, Eli Lilly and Company and/or one of its subsidiaries.

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Datum fӧr senaste ӧversyn 2021 M07 28


Kontakta Medicinsk Information på Lilly

Kontakta oss på telefon

Kontorstid vardagar 9.00-17.00

Eller så kan du

Klicka för att chatta är tillgänglig

Klicka för att chatta är offline

Skriv din fråga till oss